🎁 Black Friday: up to 50% off of annual plans
Glenmark Pharmaceuticals Limited (BOM:532296)
India flag India · Delayed Price · Currency is INR
2,648.00
+27.00 (1.03%)
At close: Nov 20, 2026

Glenmark Pharmaceuticals Balance Sheet

Millions INR. Fiscal year is Apr - Mar.

Assets

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash & Equivalents
12,90711,74716,75716,58311,59214,105
Short-Term Investments
-88.8463.4557.8190.6757.33
Cash & Short-Term Investments
12,90711,83616,82116,64111,68314,163
Cash Growth
-52.02%-29.63%1.08%42.44%-17.51%23.43%
Accounts Receivable
54,93749,63433,41918,58436,65231,011
Other Receivables
-8,9985,7108,2255,7435,576
Receivables
54,93758,63239,13026,80942,39436,588
Inventory
37,46234,30830,28525,13123,73624,998
Prepaid Expenses
-1,0051,053266.92,2752,199
Other Current Assets
21,8337,2175,6675,43427,1674,876
Total Current Assets
127,140112,99792,95574,281107,25582,823
Property, Plant & Equipment
44,17943,17438,61435,37541,95146,117
Long-Term Investments
423.53431.446057,958472.77556.64
Goodwill
847.03828.64702.66673.59736.19600.19
Other Intangible Assets
24,82224,23413,90012,67223,42722,254
Long-Term Deferred Tax Assets
13,88912,46611,24110,49718,05916,861
Other Long-Term Assets
2,7024,9472,4782,1301,8161,620
Total Assets
214,003199,079160,496143,586193,717170,833

Liabilities

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Accounts Payable
40,11137,43930,51225,35920,00422,887
Accrued Expenses
-5,4943,99412,47314,4277,168
Short-Term Debt
8,665-16,8158,3343,5003,700
Current Portion of Long-Term Debt
---1,5721,4567,286
Current Portion of Leases
1,0451,072922.62886.43830.39916.78
Current Income Taxes Payable
2,714945.29283.742,910984.98931.2
Other Current Liabilities
22,53218,8147,1436,6529,8484,005
Total Current Liabilities
75,06863,76459,67058,18651,05146,894
Long-Term Debt
--5,127-38,52125,717
Long-Term Leases
4,3644,8631,8621,5171,7712,000
Long-Term Deferred Tax Liabilities
252.7212.31585.882.85.14314.95
Other Long-Term Liabilities
22,19725,3214,7605,4053,9761,525
Total Liabilities
101,88293,96172,00565,11195,32476,452

Shareholders' Equity

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Common Stock
282.22282.2282.19282.19282.17282.17
Additional Paid-In Capital
-16,87316,86616,86616,85416,854
Retained Earnings
-99,97889,14080,16096,02693,564
Comprehensive Income & Other
111,842-12,012-17,793-18,828-18,422-19,834
Total Common Equity
112,124105,12188,49478,47994,73990,866
Minority Interest
-3.63-3.16-3.71-3.83,6533,515
Shareholders' Equity
112,121105,11888,49178,47598,39394,381
Total Liabilities & Equity
214,003199,079160,496143,586193,717170,833

Additional Metrics

Fiscal Year
TTMFY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Sep '26 Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Total Debt
14,0755,93524,72712,30946,07939,620
Net Cash (Debt)
-1,1685,901-7,9064,331-34,396-25,458
Net Cash Growth
------
Net Cash Per Share
-4.1420.90-28.0215.35-121.90-90.22
Filing Date Shares Outstanding
282.22282.2282.19282.19282.17282.17
Total Common Shares Outstanding
282.22282.2282.19282.19282.17282.17
Working Capital
52,07249,23333,28416,09556,20535,929
Book Value Per Share
397.29372.50313.60278.11335.75322.03
Tangible Book Value
86,45580,05973,89165,13470,57668,012
Tangible Book Value Per Share
306.34283.69261.85230.82250.12241.04
Land
-483.57471.82461.25423.45688.97
Buildings
-20,42318,58817,55616,06917,211
Machinery
-37,22535,61832,15532,05234,167
Construction In Progress
-4,2795,4204,19310,6589,211